Patents by Inventor Tamas Oravecz

Tamas Oravecz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MST1 KINASE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20140051681
    Abstract: Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.
    Type: Application
    Filed: May 3, 2013
    Publication date: February 20, 2014
    Inventors: David John AUGERI, Jeffrey Thomas BAGDANOFF, Simon David Peter BAUGH, Marianne CARLSEN, Kenneth Gordon CARSON, John Anthony GILLERAN, Wei HE, Tamas ORAVECZ, Konstantin SALOJIN, Leonard SUNG
  • MST1 kinase inhibitors and methods of their use
    Patent number: 8440652
    Abstract: Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 14, 2013
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: David John Augeri, Jeffrey Thomas Bagdanoff, Simon David Peter Baugh, Marianne Carlsen, Kenneth Gordon Carson, John Anthony Gilleran, Wei He, Tamas Oravecz, Konstantin Salojin, Leonard Sung
  • Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer
    Publication number: 20120316171
    Abstract: Methods and compositions for the treatment and/or management of cancer are disclosed, which comprise the use of tryptophan hydroxylase inhibitors.
    Type: Application
    Filed: November 4, 2010
    Publication date: December 13, 2012
    Inventor: Tamas Oravecz
  • MST1 KINASE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20120225857
    Abstract: Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 6, 2012
    Inventors: David John Augeri, Jeffrey Thomas Bagdanoff, Simon David Peter Baugh, Marianne Carlsen, Kenneth Gordon Carson, John Anthony Gilleran, Wei He, Tamas Oravecz, Konstantin Salojin, Leonard Sung
  • Compositions and methods for treating immunological and inflammatory diseases and disorders
    Patent number: 7825150
    Abstract: Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 2, 2010
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventor: Tamas Oravecz
  • S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA
    Publication number: 20100113530
    Abstract: Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed.
    Type: Application
    Filed: October 29, 2009
    Publication date: May 6, 2010
    Inventors: Philip Manton Brown, Constance Ann Marjory Finney, Kevin Charles Kain, Tamas Oravecz, Stephen Chris Pappas
  • S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA
    Publication number: 20100112037
    Abstract: Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed.
    Type: Application
    Filed: October 29, 2009
    Publication date: May 6, 2010
    Inventors: Max Bachrach, Constance Ann Marjory Finney, Kevin Charles Kain, Tamas Oravecz
  • COMBINATIONS COMPRISING BICYCLIC S1P LYASE INHIBITORS
    Publication number: 20100048649
    Abstract: Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent.
    Type: Application
    Filed: August 20, 2009
    Publication date: February 25, 2010
    Inventor: Tamas Oravecz
  • COMPOSITIONS AND METHODS FOR TREATING IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS
    Publication number: 20090068180
    Abstract: Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent.
    Type: Application
    Filed: September 5, 2008
    Publication date: March 12, 2009
    Inventor: Tamas Oravecz
  • Chemokine variants and methods of use
    Publication number: 20030229203
    Abstract: The present invention provides the nucleotide and amino acid sequence of truncated RANTES (3-68), which has the same amino acid sequence as the wild-type RANTES, but with a Serine/Proline truncation at positions 1 and 2 from the N-terminus, respectively. CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV (DPPIV) activity but whose natural substrates and immunological functions had not been previously defined. Several chemokines, including RANTES (regulated on activation, normal T expressed and secreted) are provided, which are substrates for human CD26. The truncated RANTES (3-68) lacked the ability of native RANTES (1-68) to increase the cytosolic calcium concentration in human monocytes, but it still induces this response in macrophages activated with macrophage colony-stimulating factor (M-CSF). RANTES (3-68) retains the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1.
    Type: Application
    Filed: March 18, 2003
    Publication date: December 11, 2003
    Inventors: Tamas Oravecz, Michael A. Norcross
  • Chemokine variants
    Patent number: 6534626
    Abstract: The present invention provide the nucleotide and amino acid sequence of truncated RANTES (3-68) which has the same amino acid sequence as the wild-type RANTES, but with a serine/proline truncation at positions 1 and 2 from the N-terminus, respectively.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: March 18, 2003
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Tamas Oravecz, Michael A. Norcross